Insights › Energy & climate › November 15, 2026
Energy & climate · Pipeline & development

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program at ObesityWeek® 2026

PR Newswire (Health) Published: Results

VENTURE Analysis Finds 74% of Participants Receiving Subcutaneous VK2735 Improved by at Least One BMI Category after 13 Weeks VK2735 Treatment Led to Improvement Across Multiple Cardiometabolic Markers SAN DIEGO, Nov. 15, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Energy & climate

See everything in Energy & climate →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.